Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors

Frontiers in Immunology

Volumn 6, Issue JAN, 2015, Pages

  Platten, Michael ^a,b   von Knebel Doeberitz, Nikolaus ^b   Oezen, Iris ^b   Wick, Wolfgang ^a,b   Ochs, Katharina ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

AhR; IDO; TDO; Tryptophan metabolism; Tumor immunity

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; GENERAL CONTROL NONDEREPRESSIBLE 2 KINASE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2, 3 DIOXYGENASE; INDOLEAMINE 2, 3 DIOXYGENASE 1; INDOLEAMINE 2, 3 DIOXYGENASE 1 INHIBITOR; INDOXIMOD; IPILIMUMAB; KYNURENINE; MAMMALIAN TARGET OF RAPAMYCIN; PROSTAGLANDIN E2; PROTEIN SERINE THREONINE KINASE; STAT1 PROTEIN; STAT3 PROTEIN; TRYPTOPHAN 2, 3 DIOXYGENASE; TRYPTOPHAN 2, 3 DIOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CATABOLISM; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MELANOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84926609039     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00673     Document Type: Review

References (56)

1. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010) 107:19961-6. doi:10.1073/pnas.1014465107
2. Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun (2008) 375:331-5. doi:10.1016/j.bbrc.2008.07.156
3. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 109:2497-502. doi:10.1073/pnas.1113873109
4. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 17:1094-100. doi:10.1038/nm.2438
5. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014) 5:1038-51.
6. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 11:312-9. doi:10.1038/nm1196
7. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 12:870-8. doi:10.1038/ni.2077
8. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo-but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2008) 111:2152-4. doi:10.1182/blood-2007-10-116111
9. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 67:792-801. doi:10.1158/0008-5472.CAN-06-2925
10. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan. Cancer Res (2007) 67:7082-7. doi:10.1158/0008-5472.CAN-07-1872
11. Travers MT, Gow IF, Barber MC, Thomson J, Shennan DB. Indoleamine 2,3-dioxygenase activity and l-tryptophan transport in human breast cancer cells. Biochim Biophys Acta (2004) 1661:106-12. doi:10.1016/j.bbamem.2003.12.004
12. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by d-1-methyl-tryptophan. Oncoimmunology (2012) 1:1460-8. doi:10.4161/onci.21716
13. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, et al. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-d-tryptophan upregulates IDO1 in human cancer cells. PLoS One (2011) 6:e19823. doi:10.1371/journal.pone.0019823
14. Meininger D, Zalameda L, Liu Y, Stepan LP, Borges L, McCarter JD, et al. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta (2011) 1814:1947-54. doi:10.1016/j.bbapap.2011.07.023
15. Soliman HH, Antonia S, Sullivan D, Vanahanian N, Link C. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-d-tryptophan (1MT). ASCO Meet Abstr (2009) 27:3004.
16. Jackson E, Dees EC, Kauh JS, Harvey RD, Neuger A, Lush R, et al. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. ASCO Meet Abstr (2013) 31:3026.
17. Jackson E, Minton SE, Ismail-Khan R, Han H, Neuger A, Antonia S, et al. A phase I study of 1-methyl-d-tryptophan in combination with docetaxel in metastatic solid tumors. ASCO Meet Abstr (2012) 30:TS2620.
18. Zakharia Y, Johnson TS, Colman H, Vahanian NN, Link CJ, Kennedy E, et al. A phase I/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors. ASCO Meet Abstr (2014) 32:TS2107.
19. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 4:1206-12. doi:10.1038/ni1003
20. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 3:1097-101. doi:10.1038/ni846
21. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4(+) T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol (2004) 172:4100-10. doi:10.4049/jimmunol.172.7.4100
22. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 210:1389-402. doi:10.1084/jem.20130066
23. Kennedy E, Rossi GR, Vahanian NN, Link CJ. Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma. ASCO Meet Abstr (2014) 32:TS9117.
24. Gibney GT, Hamid O, Gangadhar TC, Lutzky J, Olszanski AJ, Gajewski T, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. ASCO Meet Abstr (2014) 32:3010.
25. Jha GG, Miller JS. A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. ASCO Meet Abstr (2014) 32:TS5111.
26. Soliman HH, Minton SE, Ismail-Khan R, Han HS, Janssen W, Vahanian NN, et al. A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. ASCO Meet Abstr (2014) 32:TS3125.
27. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol (2012) 188:21-8. doi:10.4049/jimmunol.1101029
28. Lanzinger M, Jurgens B, Hainz U, Dillinger B, Raberger J, Fuchs D, et al. Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase. Eur J Immunol (2012) 42:1117-28. doi:10.1002/eji.201141765
29. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene (2008) 27:3889-900. doi:10.1038/onc.2008.35
30. Shoushtari AN, D'Angelo SP, Keohan ML, Dickson MA, Gounder MM, Abdullah AK, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas. ASCO Meet Abstr (2014) 32:10521.
31. Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 11:18-26. doi:10.1124/mi.11.1.4
32. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 105:20828-33. doi:10.1073/pnas.0810278105
33. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, et al. Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients. ASCO Meet Abstr (2013) 31:8084. doi:10.1158/1078-0432.CCR-13-1560
34. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 478:197-203. doi:10.1038/nature10491
35. Salter M, Hazelwood R, Pogson CI, Iyer R, Madge DJ. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem Pharmacol (1995) 49:1435-42. doi:10.1016/0006-2952(95)00006-L
36. Dolusic E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, et al. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem (2011) 54:5320-34. doi:10.1021/jm2006782
37. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain (2009) 2:8. doi:10.1186/1756-6606-2-8
38. Pantouris G, Mowat CG. Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase. Biochem Biophys Res Commun (2014) 443:28-31. doi:10.1016/j.bbrc.2013.11.037
39. Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, et al. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia (2014) 63:78-90. doi:10.1002/glia.22734
40. Wincent E, Bengtsson J, Mohammadi Bardbori A, Alsberg T, Luecke S, Rannug U, et al. Inhibition of cytochrome P4501-dependent clearance of the endogenous agonist FICZ as a mechanism for activation of the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2012) 109:4479-84. doi:10.1073/pnas.1118467109
41. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 39:372-85. doi:10.1016/j.immuni.2013.08.003
42. Moura-Alves P, Fae K, Houthuys E, Dorhoi A, Kreuchwig A, Furkert J, et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature (2014) 512:387-92. doi:10.1038/nature13684
43. Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell (2011) 147:629-40. doi:10.1016/j.cell.2011.09.025
44. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 453:65-71. doi:10.1038/nature06880
45. Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol (2009) 30:447-54. doi:10.1016/j.it.2009.06.005
46. Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L, et al. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res (2004) 64:4707-10. doi:10.1158/0008-5472.CAN-03-0875
47. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 511:184-90. doi:10.1038/nature13323
48. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 185:3190-8. doi:10.4049/jimmunol.0903670
49. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 22:633-42. doi:10.1016/j.immuni.2005.03.013
50. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 117:2570-82. doi:10.1172/JCI31911
51. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 189:1363-72. doi:10.1084/jem.189.9.1363
52. Kudo Y, Boyd CA. The role of l-tryptophan transport in l-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants. J Physiol (2001) 531:417-23. doi:10.1111/j.1469-7793.2001.0417i.x
53. Haynes BF, Hemler ME, Mann DL, Eisenbarth GS, Shelhamer J, Mostowski HS, et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 126:1409-14.
54. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature (1997) 390:81-5. doi:10.1038/36349
55. Seymour RL, Ganapathy V, Mellor AL, Munn DH. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol (2006) 80:1320-7. doi:10.1189/jlb.1205727
56. Kaper T, Looger LL, Takanaga H, Platten M, Steinman L, Frommer WB. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol (2007) 5:e257. doi:10.1371/journal.pbio.0050257